IPOG SIGNED

Project "IPOG" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Preeclampsia is responsible for the deaths of more than 70,000 mothers and half a million babies each year. Identifying those mothers at risk of preeclampsia is difficult. The current gold standard in prenatal care does not detect the disease early enough to change the course of the disease.

MDx has developed PrePsia™, a simple blood test which identifies an expectant mother’s risk of preterm preeclampsia, up to 5 months before most women will display clinical symptoms. Clinicians can now use this simple tool, to personalise pregnancy care, including the initiation of treatments in early pregnancy that can dramatically reduce the incidence of preterm preeclampsia by 62%3. In the EU, with about 5.1 million births per annum (2015 data) , treating the women identified at high risk for preterm preeclampsia by PrePsia™ has the potential to prevent over 37,000 cases of preterm preeclampsia and its associated severe outcomes, every year.

The only other test in the market that screens for preterm preeclampsia, is complex and requires for specialist ultrasound scans to be taken, which are expensive, subjective and require for dedicated ultrasound equipment and operators.

MDx has a portfolio of IP assets, as developed by the company over the last 5 years, that will protect PrePsia™ and also have significant commercial potential beyond just the realm of preeclampsia.

MDx has team of successful serial entrepreneurs coupled with globally renewed technical expertise to deliver PrePsia™ to the market and build a long term self-sustaining European company.

By year 4 MDx will have annualised revenues of €69 million and employment for 50 people while fulfilling its ambition to become a world leader in innovative pregnancy diagnostics.

 Publications